Rare Qui Tam Jury False Claims Act Case: Learning Points Regarding FCA Cases Including Eli Lilly/Astellas Pharma Verdict

Episode Date: September 14, 2022

In this episode of Stark Integrity, Bob Wade (“Captain Integrity”) explores a rare False Claims Act (FCA) case that went all the way to a jury verdict, focusing on key legal and compliance lessons—particularly those arising from the Eli Lilly and Astellas Pharma verdict.

Bob walks through why these types of cases are uncommon, what made this verdict noteworthy, and the broader implications for healthcare organizations navigating FCA risk.

Why FCA Jury Trials Are Rare

Bob begins by emphasizing that FCA jury trials are extremely rare.

Most FCA cases:

• Settle before trial
• Are resolved through government intervention
• Avoid the unpredictability of jury decisions

The primary reason is the massive financial exposure, including treble damages and per-claim penalties, which creates strong incentives to settle.

The Eli Lilly / Astellas Context

A central focus of the episode is the Eli Lilly and Astellas Pharma verdict, which serves as a real-world example of how FCA cases can play out before a jury.

Bob highlights that this case:

• Involved complex allegations tied to healthcare reimbursement
• Demonstrates how liability theories are presented to juries
• Reflects the high stakes involved when cases proceed to trial

It also underscores that even sophisticated organizations can face significant litigation risk under the FCA.

Key Legal Elements in FCA Jury Cases

Bob explains that when FCA cases reach a jury, several legal elements become critically important:

1. Causation

• Did the alleged misconduct actually lead to false claims being submitted?

2. Knowledge (Scienter)

• Did the organization act knowingly, recklessly, or with deliberate ignorance?

3. Materiality

• Would the issue have influenced the government’s payment decision?

Bob stresses that materiality is often a deciding factor, especially under modern FCA case law standards.

The Role of Qui Tam Relators

Bob also explains the importance of qui tam relators (whistleblowers) in these cases.

Key points:

• Relators bring cases on behalf of the government
• They may proceed even if the government declines intervention
• They are incentivized through a share of any recovery

In rare jury cases like this one, relators can play a leading role in taking a case all the way through trial.

The Risk of Massive Damages

One of the most important takeaways is the scale of financial exposure in FCA cases.

Bob notes that:

• Damages are automatically trebled
• Penalties apply on a per-claim basis
• Verdicts can escalate quickly into very large judgments

This is a key reason why defendants are often reluctant to go to trial.

Compliance Lessons

Bob highlights several practical compliance lessons drawn from these cases:

• Strong documentation is essential
• Internal communications matter—emails and discussions can become evidence
• Billing practices must be carefully monitored
• Financial relationships must comply with Stark and AKS requirements
• Compliance programs should be proactive, not reactive

These fundamentals are critical to mitigating FCA risk.

Strategic Considerations

Bob emphasizes that FCA cases are not just legal issues—they are strategic decisions.

Organizations must evaluate:

• Whether to settle or litigate
• The unpredictability of a jury
• Cost and duration of litigation
• Reputational impact

Taking a case to trial is a high-risk decision with potentially enormous consequences.

Practical Takeaways

The key takeaway from this episode is that rare FCA jury trials provide some of the most valuable real-world lessons for compliance. Organizations should:

• Understand how juries evaluate FCA claims
• Take whistleblower risks seriously
• Invest in strong compliance infrastructure
• Monitor high-risk areas like billing and referrals
• Carefully assess litigation strategy

Final Thoughts

Bob Wade’s discussion highlights that while FCA jury trials are rare, they offer critical insight into how these cases unfold in practice.

The Eli Lilly and Astellas Pharma verdict provides a powerful example of the risks organizations face—and reinforces the importance of strong compliance, documentation, and proactive risk management in today’s enforcement environment.

Click here to listen to this Stark Integrity Podcast Episode:
https://podcasts.apple.com/us/podcast/rare-qui-tam-jury-false-claims-act-case-learning-points/id1588939373?i=1000579412158&l=fr-FR